PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds, PetCare Rx, and PetMeds brands. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

PetMed Express выглядит как компания, у которой баланс пока ещё поддерживает бизнес, но операционная база заметно сжимается. Оценка по P/S 0.24 и P/B 1.04 выглядит дешёвой относительно отрасли, а отсутствие долгосрочного долга снижает финансовые риски. При этом P/E и P/FCF фактически не дают полезного сигнала из-за нулевых/искажённых значений, что обычно отражает слабую или нестабильную прибыльность, а не скрытую дешевизну. Выручка снизилась с 53 млн до 41 млн за несколько периодов, и это важный негативный тренд для оценки. Валовая прибыль тоже уменьшилась с 15 млн до 9 млн, а валовая маржа просела с 32.49% до 27.42%, что говорит о давлении на ценообразование или структуру затрат. Операционная прибыль и операционная маржа в TTM равны нулю, а чистая маржа также нулевая, поэтому текущая модель бизнеса не демонстрирует устойчивой операционной отдачи. EPS остаётся отрицательной, а прогноз EPS тоже слабый, что ограничивает потенциал переоценки даже при низких мультипликаторах. Ликвидность ухудшилась: current ratio снизился до 0.89, quick ratio до 0.66, то есть запас прочности по оборотному капиталу уже некомфортный. Собственный капитал сократился до 33 млн, а net worth и return on tangible equity остаются очень слабыми, что указывает на низкую эффективность использования капитала. Дивидендная доходность выглядит привлекательной, но на фоне падения выручки и прибыли её устойчивость вызывает вопросы. В сумме картина скорее защитно-негативная: баланс пока не перегружен долгом, но бизнес-моментум и рентабельность слишком слабы для агрессивного повышения целевой цены. Поэтому фундаментально прогноз стоит умеренно снизить, сохраняя консервативный взгляд на восстановление.

PetMed Express, Inc.

Дешёвые мультипликаторы PETS не компенсируют падение выручки, слабую прибыльность и ухудшение ликвидности; баланс без долга остаётся главным плюсом.

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

PetMed Express (PETS) Q4 2026 Earnings Transcript

PDD Holdings Inc. Sponsored ADR (PDD) came out with quarterly earnings of $3.08 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $3.2 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +61.26%. A quarter ago, it was expected that this company would post earnings of $2.49 per share when it actually produced earnings of $1.56, delivering a surprise of -37.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
PDD Holdings Inc. Sponsored ADR, which belongs to the Zacks Internet - Commerce industry, posted revenues of $14.52 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.15%. This compares to year-ago revenues of $13.36 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
PDD Holdings Inc. Sponsored ADR shares have added about 31.1% since the beginning of the year versus the S&P 500's gain of 10%.
What's Next for PDD Holdings Inc. Sponsored ADR?
While PDD Holdings Inc. Sponsored ADR has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for PDD Holdings Inc. Sponsored ADR was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.15 on $14.95 billion in revenues for the coming quarter and $8.70 on $59.53 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Commerce is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, PetMed (PETS), is yet to report results for the quarter ended June 2025.
This pet pharmacy company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of -133.3%. The consensus EPS estimate for the quarter has been revised 42.9% lower over the last 30 days to the current level.
PetMed's revenues are expected to be $58.71 million, down 13.6% from the year-ago quarter.
Should You Invest in PDD Holdings Inc. Sponsored ADR (PDD)?
Before you invest in PDD Holdings Inc. Sponsored ADR (PDD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PDD Holdings Inc. Sponsored ADR (PDD) Q2 Earnings and Revenues Top Estimates

PETMED EXPRESS ($PETS) is expected to release its quarterly earnings data on Monday, May 12th after market close, per Finnhub. Analysts are expecting revenue of $55,080,000 and earnings of -$0.05 per share.
You can see Quiver Quantitative's $PETS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PETMED EXPRESS Insider Trading Activity
PETMED EXPRESS insiders have traded $PETS stock on the open market 21 times in the past 6 months. Of those trades, 19 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PETS stock by insiders over the last 6 months:
CAPITAL HOLDINGS INC. NINA has made 8 purchases buying 372,000 shares for an estimated $1,706,885 and 0 sales.
LESLIE C.G. CAMPBELL has made 11 purchases buying 60,000 shares for an estimated $324,635 and 0 sales.
SANDRA YVETTE CAMPOS (CEO & President) has made 0 purchases and 2 sales selling 60,463 shares for an estimated $200,090.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PETMED EXPRESS Hedge Fund Activity
We have seen 35 institutional investors add shares of PETMED EXPRESS stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
D. E. SHAW & CO., INC. removed 149,495 shares (-46.5%) from their portfolio in Q4 2024, for an estimated $720,565
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC removed 116,600 shares (-10.7%) from their portfolio in Q4 2024, for an estimated $562,012
METAVASI CAPITAL LP added 111,194 shares (+48.5%) to their portfolio in Q4 2024, for an estimated $535,955
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 107,614 shares (+26.5%) to their portfolio in Q4 2024, for an estimated $518,699
CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 99,186 shares (-90.8%) from their portfolio in Q1 2025, for an estimated $415,589
CUBIST SYSTEMATIC STRATEGIES, LLC removed 95,309 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $459,389
SCHONFELD STRATEGIC ADVISORS LLC removed 90,500 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $436,210
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PETMED EXPRESS Earnings Preview: Recent $PETS Insider Trading, Hedge Fund Activity, and More

For Immediate Release
Chicago, IL – March 7, 2025 – Zacks Equity Research shares The Progressive PGR, as the Bull of the Day and PetMed Express PETS as the Bear of the Day. In addition, Zacks Equity Research provides analysis on — Ford F, General Motors GM and Stellantis STLA.
Here is a synopsis of all five stocks:
Bull of the Day:
2025 has already been a challenging year for the market, but one investment factor has outperformed: low volatility. Stocks with historically lower volatility have significantly outperformed, proving to be the market’s strongest segment amid uncertainty.
One of my top picks in this group is The Progressive, a stock I have consistently recommended over the past year and one that remains an attractive investment today. It not only delivers strong returns with lower volatility and defensive positioning but also holds a top Zacks Rank and steady growth forecasts, making it a compelling choice for investors looking for stability and upside.
Analysts Continue to Raise PGR Earnings Estimates
The chart below illustrates exactly why I’ve been highlighting The Progressive stock for more than a year—consistent upward revisions to its earnings estimates. Earnings revisions are the foundation of Zacks’ stock analysis, and PGR is a prime example of why they matter. Analysts began raising estimates in mid-2023, and since then, the stock has more than doubled.
More recently, analysts have unanimously raised their earnings forecasts across multiple timeframes. In just the last two months, estimates have been revised higher by as much as 17.5%, and even in the past week, projections have continued to climb. Not surprisingly, PGR enjoys a Zacks Rank #1 (Strong Buy) rating.
Progressive has also been on an encouraging streak of earnings beats. The company has exceeded analyst expectations for five consecutive quarters, and based on the Zacks Earnings ESP, it is projected to beat again next quarter by 1.27%.
The Progressive has a Reasonable Valuation
The Progressive currently trades at a one-year forward earnings multiple of 18.7x, which is only slightly above its 10-year median of 17.7x. This narrow spread suggests that, despite its strong performance, the stock is not excessively expensive relative to its historical valuation.
Such a reasonable valuation reinforces Progressive’s appeal as a sound investment, offering both attractive returns and growth potential without overpaying.
Should Investors Buy Shares in PGR?
Progressive’s combination of low volatility, strong earnings growth, and reasonable valuation makes it a standout stock in today’s uncertain market. With analysts continuing to raise earnings estimates and the company consistently delivering earnings beats, PGR remains one of the most attractive defensive plays available.
Despite its impressive rally, the stock is not overvalued relative to its historical norms, suggesting there is still room for upside. Add in its top Zacks Rank and strong industry positioning as the nation’s second largest auto insurer, the Progressive offers a compelling mix of stability, steady growth, and resilience in a challenging market environment.
For investors looking to outperform while minimizing risk, PGR remains a top-tier choice.
Bear of the Day:
PetMed Express is built around an appealing concept—capitalizing on the rapidly growing pet ownership trend by offering pet medications and health products through an online platform. In theory, the company is well positioned in a market where pet spending continues to rise. However, its execution has failed to keep pace with industry growth, and the stock’s sharp decline over the past two years reflects a business struggling to maintain momentum.
Sales and earnings have been on a steady decline, and analysts have consistently lowered earnings estimates, signaling deteriorating fundamentals. Despite this weakness, the stock still trades at a surprisingly high relative valuation, making it an even less attractive option for investors. Without a clear turnaround in revenue growth and profitability, PETS remains a stock to avoid until its fundamentals show signs of meaningful improvement.
PETS Struggles with Falling Sales and Earnings Downgrades
PetMed Express has been caught in a multi-year sales decline, and the outlook remains bleak. Annual revenue has been shrinking for the last three years, and analysts expect this trend to continue. Sales are projected to decline by 18.6% this year and another 6.8% next year, indicating persistent weakness in the company’s ability to generate growth.
Earnings expectations have also been consistently revised lower, further underscoring PetMed’s deteriorating fundamentals. In just the past month, analysts have cut their estimates for the current quarter by 20%, while full-year 2025 earnings forecasts have been slashed by 20.8%. The company now holds a Zacks Rank #5 (Strong Sell) rating, reflecting its unfavorable earnings trajectory.
The outlook for profitability is even more concerning, with earnings projected to plummet by 84% over the next year. With sales momentum fading and margins under pressure, the company faces significant hurdles to reversing its downward trajectory.
PetMed Express Valuation May Still Be Too High
Despite its ongoing struggles, PetMed Express continues to trade at a surprisingly high valuation. The stock currently carries a one-year forward earnings multiple of 21.1x, which is in line with the broader market. However, given the company's deteriorating fundamentals this valuation appears difficult to justify and could further increase the downside risk in the stock.
Should Investors Avoid PETS Stock?
With declining sales, shrinking earnings, and ongoing analyst downgrades, PetMed Express faces significant challenges that show no signs of easing. The company’s inability to capitalize on the booming pet care industry raises concerns about its long-term viability, especially as competition intensifies from larger e-commerce players and traditional pet retailers.
Despite these headwinds, PETS continues to trade at a valuation that appears too high given its weak fundamentals, making it even less attractive for investors. Until the company can stabilize its business, improve profitability, and regain earnings momentum, there is little reason to take a chance on this struggling stock. For now, PETS remains a stock to avoid, as further downside risk appears likely.
Additional content:
Will Trump's One-Month Tariff Delay for Automakers Help?
President Donald Trump’s 25% tariff on imported goods from Canada and Mexico took effect on March 4, shaking the automotive industry and sending most auto stocks into the red on Tuesday. However, yesterday, the White House announced a one-month exemption for U.S. automakers that comply with the U.S.-Mexico-Canada Agreement (USMCA). This temporary pause sparked a brief rally in auto stocks, but does it offer real relief, or is it just delaying the inevitable?
A Short-Lived Relief for Automakers
The announcement of the one-month exemption led to a swift recovery in auto stocks. Major players like Ford, General Motors and Stellantis saw their stock prices rebound after Tuesday’s losses. F, GM and STLA rose roughly 6%, 7% and 9%, respectively, reflecting investor optimism, as the exemption eased concerns about immediate cost increases and potential profit declines.
While this temporary exemption offers a brief sigh of relief, it does not erase the uncertainty looming over the industry. The reality is that once the exemption period ends, tariffs would push vehicle prices significantly higher, affecting sales and profitability.
The Impact of Tariffs on Consumers
Some reports suggest that tariffs are expected to increase vehicle prices by as much as $12,000, but only for cars that have not yet been built or imported. This poses a significant challenge for consumers already grappling with high vehicle costs.
According to Kelley Blue Book, Trump’s tariffs could raise the average new car price—already nearing $49,000—by at least $3,000, Full-size pickup trucks, a key segment for U.S. automakers, could see price hikes of up to $10,000.
This means that the current inventory on dealer lots is a temporary hedge against the expected price hikes. According to CarGurus.com, new car inventory is up 12% compared to last year, allowing consumers a short window to purchase vehicles at pre-tariff prices. However, once these cars are sold, prices could rise sharply.
Used cars remain another option, as they are also exempt from tariffs. But availability is tightening. In February, the supply of used cars was 45.2 days, a decline from January’s 49.5 days. As new vehicle prices climb due to tariffs, demand for used cars will likely rise, driving up their prices as well.
Long-Term Industry Consequences
The Big 3 automakers face varying degrees of exposure to the tariffs. GM’s Chevrolet and GMC pickups, along with Stellantis’s Ram, are particularly vulnerable due to their reliance on Mexican manufacturing. In contrast, Ford builds its F-Series trucks in the United States but still sources some key components, such as engines, from Canada.
The complex supply chain that connects the three North American economies means that no automaker is likely to be fully insulated from the impact of tariffs. While the one-month exemption delays the impact of tariffs, it isn’t solving the deeper issues they create.
Vehicles built in the United States often rely on components from Canada and Mexico. Research shows that Mexico supplies up to 40% of components used in U.S. vehicles, while Canada contributes over 20%. Tariffs on these parts will ripple through the entire supply chain, ultimately increasing costs for both manufacturers and consumers. Suppliers, already dealing with high costs, may struggle to absorb these tariffs, potentially leading to job losses and production cuts.
Industry analysts predict that prolonged tariffs could lead to production slowdowns or even shutdowns at some plants. S&P Global Mobility warns that if tariffs persist beyond eight weeks, the industry could face a scenario they call "Tariff Winter." In this case, North American light-vehicle sales could decline by 10% over several years, with Mexico and Canada also seeing significant drops.
Final Thoughts
Trump’s one-month exemption gives automakers a short break, but it doesn’t solve the bigger problems that these tariffs would eventually create. The market saw a quick boost, but the long-term impact is unclear. Once the exemption ends, costs will rise for automakers, suppliers, and consumers. If no deal is reached, higher prices are inevitable. Companies are already figuring out how to handle the extra costs, but the real question is how long the tariffs will last once enacted—and that’s anybody’s guess.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Just Released: Zacks Top 10 Stocks for 2025
Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ford Motor Company (F) : Free Stock Analysis Report
PetMed Express, Inc. (PETS) : Free Stock Analysis Report
The Progressive Corporation (PGR) : Free Stock Analysis Report
General Motors Company (GM) : Free Stock Analysis Report
Stellantis N.V. (STLA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Progressive and PetMed Express in the Box have been highlighted as Zacks Bull and Bear of the Day

(RTTNews) - PetMed Express Inc. (PETS) will host a conference call at 4:30 PM ET on February 10, 2025, to discuss Q3 25 earnings results.
To access the live webcast, log on to https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx
To listen to the call, dial 877-407-0789 (US) or 201-689-8562 (International), Webcast: 3Q Earnings Webcast.
For a replay call, dial 844-512-2921 (US) or 412-317-6671 (International), Passcode: 13750886.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express Q3 25 Earnings Conference Call At 4:30 PM ET

The three major U.S. indexes — the Nasdaq Composite, the S&P 500, and the Dow Jones Industrial Average — have declined 2.1%, 1.9%, and 1.4%, respectively, since October 28. A cautious approach ahead of the U.S. presidential election has pushed the markets into negative territory.
The Labor Department reported that the U.S. economy added only 12,000 jobs in October, reaching its lowest point in three and a half years. Although unemployment remained steady at 4.1%, weak jobs data have raised fresh concerns about the economy’s health among market participants.
Gross domestic product grew at 2.8% annually in Q3. Consumer spending, which holds more than two-thirds of economic activity, rose 3.7% annually, the highest since the first quarter of 2023. Inflation remains under check as the personal consumption expenditures (PCE) index for September came in at 2.1% annually, closer to the Federal Reserve's 2% target. The CME FedWatch Tool indicates a 100% probability of another rate cut in the upcoming Federal Open Market Committee (FOMC) meeting on November 7.
On the global front, rising tensions between Iran and Israel have flared up worries about global supply-chain disruption and impact on oil prices.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Bank of New York Mellon and Parker-Hannifin Following Zacks Rank Upgrade
Shares of Bank of New York Mellon Corporation BK have gained 10.6% (versus the S&P 500’s 1% increase) since it was upgraded to a Zacks Rank #2 (Buy) on September 3.
Another stock, Parker-Hannifin Corporation PH, which was also upgraded to a Zacks Rank #2 on September 2, has returned 6.3% (versus the S&P 500’s 1% rise) since then.
Zacks Rank, our short-term rating system, has earnings estimate revisions at its core. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +14% in the year-to-date period through October 7, 2024, vs. +22.2% for the S&P 500 index and +12.4% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.63% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The portfolio of Zacks Rank #1 stocks is an equal-weight portfolio, while the S&P 500 index is a market-cap-weighted index that has been notably distorted by the concentrated performance of mega-cap stocks since late 2022.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by almost 13 percentage points since 1988 (Through October 7, 2024, the Zacks # 1 Rank stocks generated an annualized average return of +24.1% since 1988 vs. +11.2% for the S&P 500 index).
You can see the complete list of today’s Zacks Rank #1 stocks here >>>
Check Bank of New York Mellon’ historical EPS and Sales here>>>
Check Parker-Hannifin’s historical EPS and Sales here>>>
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Ubiquiti and PetMed Express
Shares of Ubiquiti Inc. UI and PetMed Express, Inc. PETS have advanced 36.8% (versus the S&P 500’s 3.8% increase) and 28.7% (versus the S&P 500’s 4.2% rise), since their Zacks Recommendation was upgraded to Outperform on September 11 and September 10, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Cbre, Ulta Beauty Shoot Up
Shares of Cbre Group Inc. CBRE, which belongs to the Zacks Focus List, have gained 21.9% over the past 12 weeks. The stock was added to the Focus List on March 13, 2017. Another Focus-List holding, Ulta Beauty, Inc. ULTA, which was added to the portfolio on March 25, 2020, has returned 19.8% over the past 12 weeks. The S&P 500 has advanced 9% over this period.
The Focus List portfolio returned +19.7% in 2024 (through September 30th) vs. +22.1% for the S&P 500 index and +15.2% for the equal-weight S&P 500 index.
The 50-stock Zacks Focus List model portfolio returned +31.44% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio produced -15.2% vs. the S&P 500 index’s -17.96%.
Since 2004, the Focus List portfolio has produced an annualized return of +11.9% (through September 30, 2024). This compares to a +10.4% annualized return for the S&P 500 index and +10.3% for the equal-weight version of the index in the same time period.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Monster Beverage & FactSet Research Systems Make Significant Gains
Monster Beverage Corporation MNST, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 17.8% over the past 12 weeks. FactSet Research Systems Inc. FDS has followed Monster Beverage Corporation with 16.3% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +1.97% for September 2024 vs. the S&P 500 index’s +2.14% return (IVV ETF).
For the year-to-date period (through the end of September 2024), the portfolio returned +20.62% vs. +22.1% for the S&P 500 index.
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Clorox and Home Depot Outperform Peers
The Clorox Company CLX, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 14.6% over the past 12 weeks. Another ECDP stock, The Home Depot, Inc. HD, has also climbed 14.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
Check Clorox's dividend history here>>>
Check Home Depot‘s dividend history here>>>
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned +1.91% in September 2024 vs. the S&P 500 index’s +2.14% gain and the Dividend Aristocrats ETF’s (NOBL) +2.37%.
For the year-to-date period (through September 30th), the portfolio returned +15.85% vs. +22.1% for the S&P 500 index and +13.78% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stocks Stride Delivers Solid Returns
Stride, Inc. LRN, from the Zacks Top 10 Stocks for 2024, has jumped 57.3% year to date, which compares to the S&P 500 index’s +19.9% increase.
The Top 10 portfolio returned +40.9% this year through September 30th, vs. +22.1% for the S&P 500 index and +15.2% for the equal-weight version of the index.
The Top 10 portfolio returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +1,714.9% through September 30th, 2024, vs. +448.6% for the S&P 500 index. The portfolio has produced an average return of +25.5% in the period 2012 through September 30th, 2024, vs. +14.4% for the S&P 500 index and +12.7% for the equal-weight version of the index.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
PetMed Express, Inc. (PETS) : Free Stock Analysis Report
Parker-Hannifin Corporation (PH) : Free Stock Analysis Report
The Home Depot, Inc. (HD) : Free Stock Analysis Report
The Clorox Company (CLX) : Free Stock Analysis Report
Ulta Beauty Inc. (ULTA) : Free Stock Analysis Report
FactSet Research Systems Inc. (FDS) : Free Stock Analysis Report
Monster Beverage Corporation (MNST) : Free Stock Analysis Report
Stride, Inc. (LRN) : Free Stock Analysis Report
CBRE Group, Inc. (CBRE) : Free Stock Analysis Report
Ubiquiti Inc. (UI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Beat the Market the Zacks Way: Bank of New York Mellon, PetMed, Ulta Beauty in Focus

Health care stocks rose in Wednesday's premarket hours with the Health Care Select Sector SPDR Fund (XLV) advancing by 0.3% and the iShares Biotechnology ETF (IBB) 0.7% higher recently.
Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma Group (MREO) said a phase 2 study of setrusumab showed "ongoing and meaningful improvements" in the lumbar spine bone mineral density of patients with osteogenesis imperfect. Mereo BioPharma was up more than 10% pre-bell.
PetMed Express (PETS) was nearly 8% lower after late Tuesday it reported a fiscal Q4 net loss of $0.25 per diluted share
, compared with $0.01 loss per share a year earlier.
Scilex Holding (SCLX) said it signed a commitment letter with Perigrove and Graf Holdings as lenders for a $100 million, five-year term financing with royalty-based payments. Scilex Holding was nearly1% lower premarket.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Health Care Sector Update for 06/12/2024: MREO, RARE, PETS, SCLX, XLV, IBB

(RTTNews) - PetMed Express Inc. (PETS) reported Loss for its fourth quarter that increased from the same period last year
The company's bottom line totaled -$5.02 million, or -$0.25 per share. This compares with -$0.21 million, or -$0.01 per share, in last year's fourth quarter.
The company's revenue for the quarter rose 6.6% to $66.50 million from $62.41 million last year.
PetMed Express Inc. earnings at a glance (GAAP) :
-Earnings (Q4): -$5.02 Mln. vs. -$0.21 Mln. last year. -EPS (Q4): -$0.25 vs. -$0.01 last year. -Revenue (Q4): $66.50 Mln vs. $62.41 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express Inc. Q4 Loss Increases

(RTTNews) - PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (PETS) announced Monday several changes to its executive leadership team to further advance key initiatives to improve the customer experience, and to accelerate growth and profitability.
The company appointed Caroline Conegliano as Chief Operating Officer (COO) of PetMeds, in a newly created role and expansion of the executive leadership team. Conegliano brings nearly two decades of experience focused on driving strategic transformation within the consumer sector.
As COO, she will be responsible for optimizing operational performance across departments, driving strategic initiatives to support the company's growth and profitability goals, and enhancing customer service and satisfaction.
The company also appointed Umesh Sripad to the newly defined role of Chief Digital and Technology Officer. Sripad will be responsible for leading the development and implementation of digital-first strategies that enrich the customer experience while driving commerce and loyalty, ensuring reliability, performance, and security of all IT systems and infrastructure.
Further, the Company and Christine Chambers, Chief Financial Officer, Treasurer and Secretary, have entered into a transition and separation agreement under which Chambers will leave the Company in early August 2024 after the Company has filed its first quarter fiscal 2025 report.
The Company has initiated a comprehensive search for its next CFO, and in the meantime Chambers will continue in her current role including finalizing the Company's fiscal 2024 year-end, and first quarter fiscal 2025 reporting and filings, and she will assist in the transition to the new CFO.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express Appoints Caroline Conegliano To Newly Created Role Of COO

MercadoLibre (MELI) came out with quarterly earnings of $6.78 per share, beating the Zacks Consensus Estimate of $6.64 per share. This compares to earnings of $3.97 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 2.11%. A quarter ago, it was expected that this operator of an online marketplace and payments system in Latin America would post earnings of $6.66 per share when it actually produced earnings of $3.25, delivering a surprise of -51.20%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
MercadoLibre, which belongs to the Zacks Internet - Commerce industry, posted revenues of $4.33 billion for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 9.86%. This compares to year-ago revenues of $3.04 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
MercadoLibre shares have lost about 7.3% since the beginning of the year versus the S&P 500's gain of 5.2%.
What's Next for MercadoLibre?
While MercadoLibre has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for MercadoLibre: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $8.86 on $4.24 billion in revenues for the coming quarter and $34.46 on $17.7 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Commerce is currently in the top 12% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, PetMed (PETS), is yet to report results for the quarter ended March 2024.
This pet pharmacy company is expected to post quarterly earnings of $0.06 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
PetMed's revenues are expected to be $72.45 million, up 16.1% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express, Inc.

Options Strategies